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threat of geographic expansion from emerging and tradi-
tional infectious diseases has increased. UNESCO deﬁnes
an international migrant as a person living outside their
birth country for >= 12 months. The global patterns of
human migration have changed substantially in the last
half century: 1) increased # countries sending and receiving
migrants, 2) accelerated rates of migration, 3) bi-directional
migration and migration transitions, 4) diversiﬁcation of
migrant types, and 5) changes in gender patterns of
migrants. Along with these profound changes in demography,
volume, speed, and purpose of migration come unique chal-
lenges in detection, diagnosis, response and management
of infectious diseases. Even in the 21st Century infectious
diseases account for ∼25% of the global mortality burden
as well as substantial morbidity. Increasingly these diseases
are blind to geopolitical borders. Cyclical pandemics like
inﬂuenza traverse the globe more rapidly than ever; newly
emerged pathogens like SARS represent a constant challenge
to public health preparedness and response. Even old dis-
eases like tuberculosis emerge in more lethal drugresistant
forms e.g. XDR-TB. These challenges demand new paradigms
to global disease control in governance, surveillance and
response. The 2005 International Health Regulations and a
range of newly formed international networks and partner-
ships are a testament to the challenges posed by the new
era of migration. Our success in combating these microbial
threats will depend on our collective effort to organize and
respond on ‘‘supra national’’ level.
doi:10.1016/j.ijid.2010.02.1526
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Role of innate immunity in the control of HIV infection
G. Alter
MGH, Boston, USA
While the immunological correlates that contribute to
slower HIV disease progression are still unknown, epi-
demiologic data strongly suggest that particular major
histocompatibility complex (MHC) class 1 alleles (including
-B27, -B57, and others that fall within the HLA-Bw4 fam-
ily of HLA-class I B alleles) are highly enriched in subjects
who maintain undetectable viral loads in the absence of
antiretroviral therapy, Elite controllers. While these MHC
molecules interact with T-cell receptors found on cytotoxic
CD8+ T cells, they also interact with innate immune recep-
tors, such as the Killer Immunoglobulin like receptors (KIR)
found on the surface of innate cytotoxic Natural Killer (NK)
cells. Furthermore, the protective effect of MHC class I alle-
les is ampliﬁed in subjects that co-express particular KIRs,
with which they are able to interact, resulting in slower pro-
gression to AIDS in these individuals compared to those that
only possess the KIR or MHC allele alone. Thus it is plausible
that NK cells may play a central role in the control of HIV
infection. NK cells expand rapidly following acute infection,
and speciﬁc populations of KIR+ NK cells expand preferen-
tially in subjects that co-express protective KIR/MHC class 1
combinations. This speciﬁc KIR3DS1+ NK cell clonal expan-
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ion persists for up to 1 year in the peripheral circulation,
nd is associated with more aggressive containment of HIV-
iral replication in vitro, these NK cells exhibit a more
olyfunctional cytokine proﬁle, and kill MHC class 1 target
ells more more aggressively than NK cells from individuals
hat do not have the protective KIR/HLA combined geno-
ype. However, despite this early epansion of NK cells in the
eriphery, these cells do not gain access to secondary lym-
hoid organs, thus providing a safe haven within which the
irus is able to replicate unabated by the innate immune
ystem, potentially allowing the virus to establish a chronic
nfection. These data strongly suggest durable control of HIV
nfection is associated with an early aggressive deployment
f highly licensed antiviral NK cells in the periphery that
ay provide speciﬁc and non-speciﬁc control of HIV viral
eplication in acute infection, while producing large quanti-
ies of cytokines and chemokines required for the induction
f high quality adaptive immune responses that may then
aintain control of HIV replication most likely in contained
issue sites.
oi:10.1016/j.ijid.2010.02.1527
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The window between transmission and peak viremia,
rior to the establishment of viral reservoirs, is the narrow
ut critical period in which a HIV-1 vaccine must control
iral replication, prevent extensive CD4 T cell destruction
nd curb generalised immune activation. We recently pub-
ished the results of T cell studies in 4 patients, showing that
he ﬁrst HIV-1 speciﬁc T cells detectable just prior to peak
iremia can select for complete virus escape in as little as
4 days.
Mathematical modeling of these very rapid rates of T cell
scape showed that the contribution of CD8+ T cell mediated
illing of productively infected cells was earlier and signif-
cantly greater than previously described; calculating that
cells in acute HIV-1 kill as much as 35% of virus-infected
ells per day. These ﬁrst T cell responses often waned rapidly
ollowing virus escape leaving, or being succeeded by, T cell
esponses to epitopes that escaped slowly or were invari-
nt. Here, we present data from an additional 10 patients
hat extend these observations and demonstrate that early
apid escape from primary HIV-1-speciﬁc T cell responses
ccurs in the majority of patients studied, suggesting that
cells are major contributors to the control of viremia in
e th In
a
f
o
h
n
T
V
d
1
U
P
L
R
L
1
2
3
U
4
(
A
s
i
o
n
1
A
i
e
o
g
s
s
w
F
r
b
h
t
a
b
m
m
m
m
a
a
w
w
i
c
t
n
o
d
1
T
P
P
1
2
3
c
o
g
t
M
b
H
s
c
a
r
a
t
n
m
t
i
r
p
i
i
t
t
w
c
o
p
w
o
t
c
o
d
T
t
1
H
d
D20 14
cute HIV-1 infection. Additional data will be presented on
unctional avidity, phenotyping and kinetics across the group
ver the ﬁrst 6 months of infection. Discussion will focus on
ow these results, together with the studies investigating
ew immunogens may direct more effective design of HIV-1
cell vaccines. Supported by the NIAD Center for HIV/AIDS
accine Immunology grant # U19 AI067854.
oi:10.1016/j.ijid.2010.02.1528
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HIV-1 subtype C viruses elicit potent but highly type-
peciﬁc neutralizing antibodies within the ﬁrst year of
nfection. In order to determine the speciﬁcity and evolution
f these autologous neutralizing antibodies, we examined
eutralization escape in four individuals infected with HIV-
subtype C from the CAPRISA 002 cohort in Durban, South
frica. Early neutralizing responses recognized a very lim-
ted number of epitopes, with antibodies that recognize new
pitopes evolving sequentially. In addition, only two regions
f the envelope were targeted by these antibodies, sug-
esting there might be common vulnerabilities in the HIV-1
ubtype C transmitted envelope. We have shown that type-
peciﬁc responses have a short term affect on viral load
hich is lost with the emergence of viral escape mutants.
actors that contribute to the development of broadly cross-
eactive neutralizing antibodies, those which would ideally
e elicited by an HIV vaccine, are largely unknown. We
ave examined the evolution of neutralization breadth in
he CAPRISA 002 cohort, and shown that cross-neutralizing
ntibodies develop in about a quarter of infected individuals
y 3 years post-infection. Generally breadth develops incre-
entally suggesting the possibility that multiple antibodies
ediate breadth, and/or that breadth is conferred by the
aturation of a single speciﬁcity. In one case, the develop-
ent of breadth could be attributed to a single neutralizing
ntibody speciﬁcity. In the CAPRISA 002 cohort, as well as in
cross-sectional cohort of chronically infected individuals,
e have explored the targets of cross-reactive antibodies
hich mediate breadth using an array of methodologies
ncluding peptide and protein adsorptions and the use of
himeric viruses. We have shown that multiple epitopes on
he envelope glycoprotein are involved in the cross-reactive
eutralization elicited during natural HIV-1 infection, many
f which are yet to be determined.
oi:10.1016/j.ijid.2010.02.1529 i
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Even with a growing recognition that HIV doesn’t dis-
riminate by race, gender, socioeconomic status or sex
rientation, the developing world accounts for 90% of the
lobal HIV burden. Sub-Saharan Africa, which accounts for
wo-thirds of the global HIV infections, Injecting Drug Users,
en who have Sex with Men, and Commercial Sex Workers
are a disproportionate burden of the HIV epidemic. Recent
IV surveillance studies in African countries at best show
tabilization of the epidemic or at worst, slight increases in
ountries like Uganda.
Clearly, the HIV research community recognizes that
dditional new biomedical prevention modalities are
equired to augment existing HIV prevention strategies.
Incidence modeling based on as relatively low efﬁcacy
s 30% for a Pre-Exposure Prophylaxis (PrEP) regimen or a
opical Microbicide has provides a glimmer of hope based on
umber of new HIV infections prevented through such new
odalities. However, scientists need to prove efﬁcacy for
hese new regimens ﬁrst.
Several international collaborations with the develop-
ng world have been formed to enable us conduct clinical
esearch that meets international standards. Phase IIB and
hase III HIV PrEP and Microbicide trials are being conducted
n nine countries globally, involving over 20,000 participants
n the various high risk groups and across different HIV
ransmission routes. Each study is being overseen by regula-
ory agencies both within the developing and the developed
orld.
The major lessons learned to date are that; North-South
ollaborative partnerships are critical to realizing the hope
f ﬁnding new prevention modalities to be added to the HIV
revention tool kit for the most-at-risk groups. Secondly,
ith these collaborations, the developing world has devel-
ped capacity to conduct of clinical research that conforms
o international standards for licensure of new products or
hange of indication of existing drugs/products in the devel-
ping world.
oi:10.1016/j.ijid.2010.02.1530
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It has been exactly 500 years since the ﬁrst recognized
nﬂuenza pandemic appeared and spread around the world
n 1510. Since that time, at least 13 additional inﬂuenza
